IHS Chemical Week

People & Business :: Companies

DSM Biologics and Crucell Enter Licensing Deal

2:08 PM MDT | August 20, 2007 | Michelle Bryner

DSM Biologics and Crucell (Leiden, the Netherlands) have entered into an agreement to license a new manufacturing technology based on the companies’ jointly developed PER.C6 cell line, to LFB Biotechnologies (Paris). Financial details were not disclosed. LFB will use the licensed technology to develop undisclosed antibodies. The companies will also evaluate the potential for a joint collaboration to develop sugar structures on recombinant antibodies using LFB’s proprietary technology. PER.C6 is a human cell line for producing therapeutic recombinant...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa